Search

Displaying results 4501 - 4510 of 10000 in total
  1. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.

  2. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline acts on a number of α adrenergic receptors. It is an agonist of α1A, partial agonist of α1B and α1D, and a nonselective antagonist of α2. … Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.

  3. Drug

    Cinchophen

    go.drugbank.com/drugs/DB13551
    Experimental

    Categories: Preparations With No Effect on Uric Acid Metabolism
  4. Drug

    Dibutylphthalate

    go.drugbank.com/drugs/DB13716
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Gallium citrate

    go.drugbank.com/drugs/DB17893
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Oxidized cellulose

    go.drugbank.com/drugs/DB13570
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Peruvoside

    go.drugbank.com/drugs/DB13756
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Coumarin 120

    go.drugbank.com/drugs/DB08168
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Saralasin

    go.drugbank.com/drugs/DB06763
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).